- Home
- WORX vs WINT Comparison
WORX vs WINT Comparison
Compare WORX & WINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WORX
- WINT
- Stock Information
- Founded
- WORX N/A
- WINT 1992
- Country
- WORX United States
- WINT United States
- Employees
- WORX N/A
- WINT N/A
- Industry
- WORX Services-Misc. Amusement & Recreation
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WORX Consumer Discretionary
- WINT Health Care
- Exchange
- WORX Nasdaq
- WINT Nasdaq
- Market Cap
- WORX N/A
- WINT 1.5M
- IPO Year
- WORX N/A
- WINT 1995
- Fundamental
- Price
- WORX $0.66
- WINT $1.20
- Analyst Decision
- WORX
- WINT Hold
- Analyst Count
- WORX 0
- WINT 1
- Target Price
- WORX N/A
- WINT $350.00
- AVG Volume (30 Days)
- WORX 31.4K
- WINT 7.7M
- Earning Date
- WORX 11-14-2024
- WINT 04-15-2025
- Dividend Yield
- WORX N/A
- WINT N/A
- EPS Growth
- WORX N/A
- WINT N/A
- EPS
- WORX N/A
- WINT N/A
- Revenue
- WORX $3,224,146.00
- WINT N/A
- Revenue This Year
- WORX N/A
- WINT N/A
- Revenue Next Year
- WORX N/A
- WINT N/A
- P/E Ratio
- WORX N/A
- WINT N/A
- Revenue Growth
- WORX N/A
- WINT N/A
- 52 Week Low
- WORX $0.67
- WINT $1.10
- 52 Week High
- WORX $4.44
- WINT $737.50
- Technical
- Relative Strength Index (RSI)
- WORX 30.78
- WINT 27.23
- Support Level
- WORX $0.67
- WINT $1.22
- Resistance Level
- WORX $0.79
- WINT $2.17
- Average True Range (ATR)
- WORX 0.05
- WINT 0.32
- MACD
- WORX 0.02
- WINT 0.20
- Stochastic Oscillator
- WORX 9.03
- WINT 3.54
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.